The partnership aims to advance the development of a first-in-class fully human anti-HER2/TROP2 BsADC for cancer treatments. Credit: Spectral-Design/shutterstock.com.

Biocytogen Pharmaceuticals and Radiance Biopharma have signed an exclusive option and licence agreement for a bispecific antibody-drug conjugate (BsADC).

The partnership aims to advance the development, manufacture and commercialisation of a first-in-class fully human anti-human epidermal growth factor receptor-2 (HER2)/tumour-associated calcium signal transducer 2 (TROP2) BsADC for cancer treatments globally.

Go deeper with GlobalData

Premium Insights

The gold standard of business intelligence.

Find out more

Radiance Biopharma will have the option to license Biocytogen’s ADC, targeting tumour-associated antigens HER2 and TROP2.

These antigens are frequently expressed and co-expressed by cancer types including non-small-cell lung cancer, breast and gastric cancers.

Radiance managing director and chairman of the board Marc Lippman stated: “We are excited to enter into this exclusive option and licence agreement with Biocytogen for a novel human anti-HER2 and Trop2 bispecific antibody-drug conjugate.

See Also:

“Preclinical data from in vitro and in vivo assays of this BsADC shows promising high potency of anti-tumour activities in leading tumour indications. We are eager to work with Biocytogen to move the product to the clinic to benefit patients.”

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Upon Radiance exercising the option, Biocytogen will receive an option fee, licensing fee and payments related to development and commercial milestones. The deal also includes single-digit royalties on net sales.

Biocytogen president and CEO Dr Yuelei Shen stated: “We are excited to collaborate with Radiance, a strong team with extensive experience in drug development, to develop a leading proprietary fully human bispecfic antibody-drug conjugate.

“We are optimistic that the combination of our strength in BsADC discovery and the extensive experience of Radiance’s team will help expedite the commercialisation of this dual-targeting BsADC.”

In December 2023, Biocytogen signed an antibody agreement with Spanish biotech company Ona Therapeutics for the development of ADCs for solid tumours.